PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Vascular SMC proliferation is a crucial event in occlusive cardiovascular diseases. PPARalpha is a nuclear receptor controlling lipid metabolism and inflammation, but its role in the regulation of SMC growth remains to be established. Here, we show that PPARalpha controls SMC cell-cycle progression at the G1/S transition by targeting the cyclin-dependent kinase inhibitor and tumor suppressor p16(INK4a) (p16), resulting in an inhibition of retinoblastoma protein phosphorylation. PPARalpha activates p16 gene transcription by both binding to a canonical PPAR-response element and interacting with the transcription factor Sp1 at specific proximal Sp1-binding sites of the p16 promoter. In a carotid arterial-injury mouse model, p16 deficiency results in an enhanced SMC proliferation underlying intimal hyperplasia. Moreover, PPARalpha activation inhibits SMC growth in vivo, and this effect requires p16 expression. These results identify an unexpected role for p16 in SMC cell-cycle control and demonstrate that PPARalpha inhibits SMC proliferation through p16. Thus, the PPARalpha/p16 pathway may be a potential pharmacological target for the prevention of cardiovascular occlusive complications of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“Initially, p16 was identified by virtue of its ability to inhibit G1/S cell-cycle progression by binding to CDK4, thus preventing CDK4 association with D-type cyclins and further initiation of pRB phosphorylation by the cyclin D/CDK4 complexes (8, 9, 27).”
BackgroundRubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“Moreover, in the secondary prevention Veterans Administration–HDL-Cholesterol Intervention Trial (VA-HIT), a decreased incidence of cardiovascular events following fibrate treatment was observed, which could not be attributed only to the effects of drug treatment on HDL levels (37).”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“PPARα mediates their systemic metabolic effects by regulating genes encoding proteins involved in lipid and lipoprotein metabolism (20).”
BackgroundSelf-citationPeroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568 · cited 3×
“Finally, the in vivo role of p16 in mediating the growth-inhibitory effects of PPARα activation were further analyzed using p16–/– mice (29).”
BackgroundMethodSelf-citationThe INK4A/ARF locus and its two gene products.
Sharpless, N. E., & DePinho, R. A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80004-5 · Cited by 533 · cited 2×
“Several studies have established that loss of p16 function can be an early event in tumor progression (42, 43) and that it is associated with tumor development (29, 44, 45).”
BackgroundMarx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Self-citation
Cited by
Senescence in Health and Disease
He, S., & Sharpless, N. E. (2017) · Cell · doi:10.1016/j.cell.2017.05.015 · Cited by 1,766
Sorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Burd, C. E., Jeck, W. R., Liu, Y., Sanoff, H. K., Wang, Z., & Sharpless, N. E. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001233 · Cited by 902
Feige, J. N., Gelman, L., Michalik, L., Desvergne, B., & Wahli, W. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.12.002 · Cited by 786
Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice
Visel, A., Zhu, Y., May, D., Afzal, V., Gong, E., Attanasio, C., Blow, M. J., Cohen, J. C., Rubin, E. M., & Pennacchio, L. A. (2010) · Nature · doi:10.1038/nature08801 · Cited by 462
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
The Molecular Balancing Act of p16INK4a in Cancer and Aging
LaPak, K. M., & Burd, C. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 291
INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis
Liu, Y., Sanoff, H. K., Cho, H., Burd, C. E., Torrice, C., Mohlke, K. L., Ibrahim, J. G., Thomas, N. E., & Sharpless, N. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005027 · Cited by 248
“In support of this notion, mice lacking p16 have been shown to be more sensitive to vascular intimal hyperplasia in a carotid artery injury model [27], suggesting that p16 protects against atherogenesis by limiting a pathologic vascular reaction to injury in some circumstances.”
BackgroundFruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233
Self-citationSarkar, J., Gou, D., Turaka, P., Viktorova, E., Ramchandran, R., & Raj, J. U. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00201.2010 · Cited by 216
Wagner, K.-D., & Wagner, N. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.001 · Cited by 189
Hannou, S. A., Wouters, K., Paumelle, R., & Staels, B. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.01.008 · Cited by 159
Self-citationMotterle, A., Pu, X., Wood, H., Xiao, Q., Gor, S., Liang Ng, F., Chan, K., Cross, F., Shohreh, B., Poston, R. N., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds224 · Cited by 160
PPARγ accelerates cellular senescence by inducing p16INK4α expression in human diploid fibroblasts
Gan, Q., Huang, J., Zhou, R., Niu, J., Zhu, X., Wang, J., Zhang, Z., & Tong, T. (2008) · Journal of Cell Science · doi:10.1242/jcs.026633 · Cited by 82
“at position –1023 relative to the translation initiation site (Gizard et al., 2005).”
BackgroundMethodInfluentialMeta-analysis of primary target genes of peroxisome proliferator-activated receptors
Heinäniemi, M., Uski, J. O., Degenhardt, T., & Carlberg, C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-7-r147 · Cited by 71
“Finally, the cyclin-dependent kinase inhibitor 2A (CDKN2A) [56] gene represents cluster IVE, in which strong or medium non-conserved REs are found in mouse and but only weak REs are found in human.”
BackgroundBouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51
Self-citation
Metadata
- Authors
- Gizard, F., Amant, C., Barbier, O., Bellosta, S., Robillard, R., Percevault, F., Sevestre, H., Krimpenfort, P., Corsini, A., Rochette, J., Glineur, C., Fruchart, J.-C., Torpier, G., & Staels, B.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-11-01
- Volume
- 115
- Issue
- 11
- Pages
- 3228-3238
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2162508286
- Cited by
- 160
- References
- 13
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.